Dose-adjusted EPOCH plus rituximab is an effective regimen in patients with poor-prognostic untreated diffuse large B-cell lymphoma: results from a prospective observational study.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples